Mr. James R. McCullough

• 
  diabeticinformation.net/sindicator/index.php - [Cached Version]
  Published on: 3/9/2007    Last Visited: 3/9/2007  

  AusAm Biotechnologies CEO James McCullough to be Featured Guest on Biotech Today

• 
  www.aleutiancapital.com/restructuring-advisory.html - [Cached Version]
  Published on: 11/4/2005    Last Visited: 8/27/2008  

  James McCullough - Director
  
  James McCullough - Director
  
  James McCullough is an experienced finance and management professional with significant expertise in turnarounds and distressed situations.
  
  In a previous role as general partner of the Renwick Special Situations Fund, Mr. McCullough led numerous engage-ments and investments focused on advising a variety of consumer electronics, technology and telecommunications companies on operational, strategic, financial and turnaround strategies.Mr. McCullough recently served as chief executive officer of AusAm Biotechnologies, a company developing innovative treat-ments for kidney, cardiovascular and infectious diseases, where he helped guide the company through its Chapter 11 bankruptcy filing and was instrumental in the sale of the company's diagnostic and therapeutic businesses.Mr. McCullough continues to be involved with a variety of technology companies and other ventures.
  
  Mr. McCullough holds a BA from Boston University and an MBA from Columbia Business School.He is an instrument rated private pilot and avid skier.He resides in New York City.

• 
  - [Cached Version]
  Published on: 10/12/2008    Last Visited: 8/21/2008  

  James R. McCullough 40-44
  
  James is currentlythe Chief Executive Officer of Exosome Diagnostics, Inc., a life sciences company commercializing genetic based diagnostics for early detection and monitoring of cancer and metabolic diseases.Exosome Diagnostics uses proprietary technology developed at Harvard University and Massachusetts General Hospital to identify genetic mutations in blood which are specific for cancer subtype, progression rate and susceptibility to drug intervention.From March of 2001 to October of 2006, Mr. McCullough was the Chief Executive Officer of AusAm Biotechnologies, Inc. a biotechnology company developing diagnostics and therapeutics to identify and treat kidney, cardiovascular and infectious diseases.At AusAm, Mr. McCullough oversaw commercial development, FDA clearance and the execution of a worldwide distribution agreement with Quest Diagnostics for Accumin, a diagnostic for detection of patients at risk for early stage kidney and cardiovascular disease.In addition, Mr. McCullough oversaw capital financing of $16 million and built a world class management, board of directors and scientific advisory team from senior executives of Quest Diagnostics, Johnson & Johnson, Bayer, the World Health Organization, The National Kidney Foundation, the Food & Drug Administration, National Institutes of Health, Lehman Brothers, and Trust Company of the West.From 1995 to 2000, Mr. McCullough served as a General Partner in the Renwick Special Situations Fund, L.P., a private partnership focusing on investments in early stage technology companies.Mr. McCullough is currently an Executive-in-Residence at Hudson/Brightwaters, a life sciences merchant bank with offices New York and Los Angeles and serves as a Director of Aleutian Restructuring Group, LLC, a management consulting advisory firm.He received his B.A. from Boston University in 1990, and his MBA from the Columbia Graduate School of Business in 1995.Mr. McCullough is an instrument rated private pilot and avid skier.He currently resides in New York City.

• 
  Albuminuria news: microalbuminuria, kidney diseases,... - [Cached Version]
  Published on: 3/6/2003    Last Visited: 11/25/2005  

  AusAm Biotechnologies CEO James Mccullough to be Featured Guest on Biotech Today Dec 15 2003

• 
  AusAm's Accumin Urine Test for Indicator of Potential... - [Cached Version]
  Published on: 9/29/2004    Last Visited: 9/30/2004  

  This gives us access to a broader physician pool to effectively diagnose microalbuminuria," said James R. McCullough, chief executive officer of AusAm Biotechnologies.

• 
  Ausam Biotechnologies Receives Contract Grant from... - [Cached Version]
  Published on: 2/24/2004    Last Visited: 2/24/2004  

  "We look forward to building on our three-year-old collaboration with the NIH to move DES10 toward clinical trials," said James R. McCullough, Chief Executive Officer of AusAm Biotechnologies, Inc.

• 
  BioSpace offers Pharmaceutical, Biotechnology and... - [Cached Version]
  Published on: 3/7/2003    Last Visited: 12/16/2003  

  AusAm Biotechnologies CEO James McCullough To Be Featured Guest On Biotech Today

• 
  Diagnostic Industry Veteran Mark R. Straley Joins... - [Cached Version]
  Published on: 8/3/2004    Last Visited: 8/6/2004  

  The company is focused on the roll-out and implementation of this test around the world," said James McCullough, Chief Executive Officer at AusAm Biotechnologies, Inc.

• 
  Finance: NIH funds development of topical drug to... - [Cached Version]
  Published on: 3/25/2004    Last Visited: 4/6/2004  

  "We look forward to building on our 3-year-old collaboration with the NIH to move DES10 toward clinical trials," said James R. McCullough, CEO of AusAm Biotechnologies, Inc.

• 
  Glenn Sherman Joins AusAm Board of Directors - [Cached Version]
  Published on: 2/19/2004    Last Visited: 2/19/2004  

  "We are delighted that Glenn Sherman has agreed to serve on AusAm's Board of Directors," said James McCullough, Chief Executive Officer at AusAm Biotechnologies, Inc.

Page:  1 2